| Literature DB >> 34373601 |
Daisuke Yamada1, Masahiro Nakamura2, Tomoka Takao1, Shota Takihira1,3, Aki Yoshida3, Shunsuke Kawai4, Akihiro Miura1, Lu Ming1, Hiroyuki Yoshitomi4,5, Mai Gozu5, Kumi Okamoto5, Hironori Hojo6, Naoyuki Kusaka7, Ryosuke Iwai7, Eiji Nakata3, Toshifumi Ozaki3, Junya Toguchida4,5, Takeshi Takarada8.
Abstract
Current protocols for the differentiation of human pluripotent stem cells (hPSCs) into chondrocytes do not allow for the expansion of intermediate progenitors so as to prospectively assess their chondrogenic potential. Here we report a protocol that leverages PRRX1-tdTomato reporter hPSCs for the selective induction of expandable and ontogenetically defined PRRX1+ limb-bud-like mesenchymal cells under defined xeno-free conditions, and the prospective assessment of the cells' chondrogenic potential via the cell-surface markers CD90, CD140B and CD82. The cells, which proliferated stably and exhibited the potential to undergo chondrogenic differentiation, formed hyaline cartilaginous-like tissue commensurate to their PRRX1-expression levels. Moreover, we show that limb-bud-like mesenchymal cells derived from patient-derived induced hPSCs can be used to identify therapeutic candidates for type II collagenopathy and we developed a method to generate uniformly sized hyaline cartilaginous-like particles by plating the cells on culture dishes coated with spots of a zwitterionic polymer. PRRX1+ limb-bud-like mesenchymal cells could facilitate the mass production of chondrocytes and cartilaginous tissues for applications in drug screening and tissue engineering.Entities:
Year: 2021 PMID: 34373601 DOI: 10.1038/s41551-021-00778-x
Source DB: PubMed Journal: Nat Biomed Eng ISSN: 2157-846X Impact factor: 25.671